[
    [
        {
            "time": "2018-03-15",
            "original_text": "Health Care Stocks Gurus Are Buying",
            "features": {
                "keywords": [
                    "health",
                    "care",
                    "stocks",
                    "gurus",
                    "buying"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Health Care Stocks Gurus Are Buying",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Here's Why Antares Pharma Jumped Higher Today",
            "features": {
                "keywords": [
                    "antares",
                    "pharma",
                    "jumped",
                    "higher"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why Antares Pharma Jumped Higher Today",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Here's Why Antares Pharma Jumped Higher Today",
            "features": {
                "keywords": [
                    "antares",
                    "pharma",
                    "jumped",
                    "higher"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why Antares Pharma Jumped Higher Today",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Examining the Performances of Eli Lilly’s Oncology Products",
            "features": {
                "keywords": [
                    "examining",
                    "performances",
                    "eli",
                    "lilly",
                    "oncology",
                    "products"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Examining the Performances of Eli Lilly’s Oncology Products",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental",
            "features": {
                "keywords": [
                    "zacks",
                    "analyst",
                    "blog",
                    "exxonmobil",
                    "disney",
                    "abbvie",
                    "bristol-myers",
                    "united",
                    "continental"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "entertainment",
                    "pharmaceuticals",
                    "transportation"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "How Eli Lilly’s Cardiovascular Products Have Been Faring",
            "features": {
                "keywords": [
                    "eli",
                    "lilly",
                    "cardiovascular",
                    "products",
                    "faring"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "cardiovascular"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "How Eli Lilly’s Cardiovascular Products Have Been Faring",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-25",
            "original_text": "IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "important",
                    "deadline",
                    "reminder",
                    "schall",
                    "law",
                    "firm",
                    "class",
                    "action",
                    "lawsuit",
                    "abbvie",
                    "investors",
                    "losses"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]